新冠肺炎危重症患者应激性溃疡并发症的合理防治  

Prevention and Treatment of Stress Ulcer Complications in Severe COVID-19 Patients

作　　者：金鑫[1] JIN Xin(Department of Hepatoliliarg Surgerg,Foorth Medical Center,General Hospital of Chinese PLA,Beijing 100048,China)

机构地区：[1]解放军总医院第四医学中心肝胆外科,北京100048

出　　处：《中国合理用药探索》2020年第3期12-15,共4页Chinese Journal of Rational Drug Use

摘　　要：新冠肺炎危重症患者比例达15.74%,其常见并发症包括肺炎、急性呼吸窘迫综合征和休克等。对于危重症患者,持续性使用机械通气,酌情考虑使用大剂量激素。急性呼吸窘迫综合征和休克都是应激性黏膜病变的危险因素,可导致应激性黏膜病变的发生。质子泵抑制剂是临床常用的抑制胃酸分泌的药物,是临床指南推荐的应激性黏膜病变的首选药物。然而,近年来质子泵抑制剂的不合理使用问题凸显。因此,临床上应合理选择质子泵抑制剂,预防新冠肺炎危重症患者应激性黏膜病变的发生。The proportion of critically ill patients with COVID-19 was 15.74%,and the common complications included pneumonia,acute respiratory distress syndrome and shock.For critically ill patients,continuous use of mechanical ventilation,the appropriate use of large doses of hormones,acute respiratory distress syndrome and shock are risk factors for stress-induced mucosal disease,which can lead to stress-related mucosal lesions.Proton pump inhibitors(PPI)are drugs commonly used to inhibit gastric acid secretion and are the preferred drugs recommended by clinical guidelines for stress-related mucosal disease.However,in recent years,the inappropriate use of proton pump inhibitors has become prominent.Therefore,proton pump inhibitors should be rationally selected to prevent stress-related mucosal disease in critically ill patients with COVID-19.

关 键 词：新冠肺炎(COVID-19) 并发症 应激性黏膜病变 质子泵抑制剂 合理用药 

分 类 号：R978.2[医药卫生—药品]